Paper33859638
Cancer Vaccines, Adjuvants, and Delivery Systems.
Paston SJ and 3 others. Front Immunol, 2021. Cited by 156 papers, by iCite.
Cite this record
ConductScience Library. Cancer Vaccines, Adjuvants, and Delivery Systems. Papers, record 33859638. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33859638
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adjuvants, Immunologic | Major topic |
| Antigens, Neoplasm | Major topic |
| Cancer Vaccines | Major topic |
| Drug Delivery Systems | Major topic |
| Gene Transfer Techniques | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Drug Carriers | |
| Drug Compounding | |
| Humans | |
| Tumor Escape | |
| Tumor Microenvironment | |
| Vaccines, DNA | |
| Vaccines, Synthetic | |
| mRNA Vaccines |
Source PubMed
References278
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17616674 | Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. | Cancer Res | 2007 | https://conductscience.org/library/papers/17616674 | PubMed |
| 2 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 3 | 14613989 | Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14613989 | PubMed |
| 4 | 1545867 | Genetic immunization is a simple method for eliciting an immune response. | Nature | 1992 | https://conductscience.org/library/papers/1545867 | PubMed |
| 5 | 16914222 | Cationic lipids, lipoplexes and intracellular delivery of genes. | J Control Release | 2006 | https://conductscience.org/library/papers/16914222 | PubMed |
| 6 | 25959818 | Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. | Cell Rep | 2015 | https://conductscience.org/library/papers/25959818 | PubMed |
| 7 | 23348506 | Highly recurrent TERT promoter mutations in human melanoma. | Science | 2013 | https://conductscience.org/library/papers/23348506 | PubMed |
| 8 | 29472691 | A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. | Cell Res | 2018 | https://conductscience.org/library/papers/29472691 | PubMed |
| 9 | 29321773 | The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. | Front Immunol | 2017 | https://conductscience.org/library/papers/29321773 | PubMed |
| 10 | 32728218 | An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. | Nature | 2020 | https://conductscience.org/library/papers/32728218 | PubMed |
| 11 | 10961895 | Prognostic significance of survivin expression in diffuse large B-cell lymphomas. | Blood | 2000 | https://conductscience.org/library/papers/10961895 | PubMed |
| 12 | 26214521 | Therapeutic cancer vaccines. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26214521 | PubMed |
| 13 | 10727458 | Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. | J Exp Med | 2000 | https://conductscience.org/library/papers/10727458 | PubMed |
| 14 | 25428507 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. | Nature | 2014 | https://conductscience.org/library/papers/25428507 | PubMed |
| 15 | 21665146 | Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. | Cancer Cell | 2011 | https://conductscience.org/library/papers/21665146 | PubMed |
| 16 | 22808118 | Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. | PLoS One | 2012 | https://conductscience.org/library/papers/22808118 | PubMed |
| 17 | 21567378 | Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. | Arthritis Rheum | 2011 | https://conductscience.org/library/papers/21567378 | PubMed |
| 18 | 26291480 | A7RC peptide modified paclitaxel liposomes dually target breast cancer. | Biomater Sci | 2015 | https://conductscience.org/library/papers/26291480 | PubMed |
| 19 | 8183550 | Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. | Oncogene | 1994 | https://conductscience.org/library/papers/8183550 | PubMed |
| 20 | 24048523 | MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. | Sci Transl Med | 2013 | https://conductscience.org/library/papers/24048523 | PubMed |
Cited by121
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 156 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42898410 | Platform-based manufacturing of tumor-infiltrating lymphocytes derived from different solid tumor types. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898410 | PubMed |
| 42670587 | Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential. | FASEB J | 2026 | https://conductscience.org/library/papers/42670587 | PubMed |
| 42646710 | The State-of-the Art of Personalized Vaccines for Non-Communicable Diseases: A Narrative Review. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42646710 | PubMed |
| 42506595 | Immunogenicity of an Oil-in-Water Emulsion Containing Hafnia Alvei-Derived Lipopolysaccharide, with TLR4 and Dectin-2 Agonist Activity In Vitro. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506595 | PubMed |
| 42494420 | Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42494420 | PubMed |
| 42481451 | Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42481451 | PubMed |
| 42328446 | RMAD1, a Novel Cell-Penetrating Peptide Derived from ADARB2: Preclinical Insights into Antigen Uptake and T Cell Activation. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42328446 | PubMed |
| 42327740 | Identification of tumor-associated antigens with multi-cancer therapeutic potential. | Front Immunol | 2026 | https://conductscience.org/library/papers/42327740 | PubMed |
| 42257193 | Synthetic Polymers for Drug, Gene, and Vaccine Delivery. | Polym Sci Technol | 2025 | https://conductscience.org/library/papers/42257193 | PubMed |
| 41946315 | Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency. | Biomaterials | 2026 | https://conductscience.org/library/papers/41946315 | PubMed |
| 41810102 | Tumor Vaccines in Hepatocellular Carcinoma: Advances, Challenges, and the Path Toward Precision Immunotherapy. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/41810102 | PubMed |
| 41669116 | Leveraging T cells for cancer immunotherapy. | Immun Inflamm | 2025 | https://conductscience.org/library/papers/41669116 | PubMed |
| 41621014 | CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41621014 | PubMed |
| 41614820 | Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41614820 | PubMed |
| 41309533 | Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41309533 | PubMed |
| 41286148 | Targeting SOX9: designing a novel vaccine against triple-negative breast cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/41286148 | PubMed |
| 41146660 | Biomimetic nanovesicle vaccines derived from dendritic cells sensitized with whole tumor antigens for melanoma immunotherapy. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41146660 | PubMed |
| 41132679 | Insights into tumor vaccines for elderly individuals in the context of immunosenescence. | Front Immunol | 2025 | https://conductscience.org/library/papers/41132679 | PubMed |
| 41072409 | Super-adjuvant nanoparticles for platform cancer vaccination. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/41072409 | PubMed |
| 41063530 | Research hotspots and trends in tumor vaccine adjuvants: A bibliometric analysis from 2010 to 2024. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/41063530 | PubMed |
Genes60
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33859638
GET https://conductscience.org/api/papers/v1/33859638/references?page=2